Dr. Adusumilli on the Rationale for Mesothelin-Targeted CAR T-Cell Therapy
April 11th 2019
Prasad S. Adusumilli, MD, surgeon, deputy chief of Thoracic Service, co-director of the Mesothelioma Program, head of Solid Tumors Cell Therapy, Cellular Therapeutics Center, at Memorial Sloan Kettering Cancer Center, discusses the rationale for an autologous mesothelin-targeted CAR T-cell therapy in advanced solid tumors.